公开(公告)号：US10233421B2

公开(公告)日：2019-03-19

申请号：US15457893

申请日：2017-03-13

Applicant: Janssen Biotech, Inc.

Inventor： Janet Davis ,  Jiajian Liu ,  Christine Parmenter ,  Pascal Ghislain Andre Bonnet

IPC: C12N5/071 ,  C12N5/0735

Abstract: The present invention is directed to methods to differentiate pluripotent stem cells. In particular, the present invention is directed to methods and compositions to differentiate pluripotent stem cells into cells expressing markers characteristic of the definitive endoderm lineage comprising culturing the pluripotent stem cells in medium comprising a sufficient amount of GDF-8 to cause the differentiation of the pluripotent stem cells into cells expressing markers characteristic of the definitive endoderm lineage.

公开(公告)号：US20130337564A1

公开(公告)日：2013-12-19

申请号：US13917109

申请日：2013-06-13

Applicant: Janssen Biotech, Inc.

Inventor： Janet Davis ,  Jiajian Liu

IPC: C12N5/071

CPC classification number: C12N5/0676 ,  C12N2500/02 ,  C12N2501/105 ,  C12N2501/115 ,  C12N2501/16 ,  C12N2501/415 ,  C12N2506/02

Abstract: The present invention is directed to methods to treat pluripotent cells, whereby the pluripotent cells can be efficiently expanded in culture and differentiated by treating the pluripotent cells with an inhibitor of GSK-3B enzyme activity.

Abstract translation: 本发明涉及治疗多能细胞的方法，其中多能细胞可以通过用GSK-3B酶活性抑制剂处理多能细胞而在培养中有效扩增并分化。

公开(公告)号：US10351820B2

公开(公告)日：2019-07-16

申请号：US15457864

申请日：2017-03-13

Applicant: Janssen Biotech, Inc.

Inventor： Janet Davis ,  Jiajian Liu ,  Christine Parmenter ,  Pascal Ghislain Andre Bonnet

IPC: C12N5/071 ,  C12N5/0735

Abstract: The present invention is directed to methods to differentiate pluripotent stem cells. In particular, the present invention is directed to methods and compositions to differentiate pluripotent stem cells into cells expressing markers characteristic of the definitive endoderm lineage comprising culturing the pluripotent stem cells in medium comprising a sufficient amount of GDF-8 to cause the differentiation of the pluripotent stem cells into cells expressing markers characteristic of the definitive endoderm lineage.

公开(公告)号：US20170183625A1

公开(公告)日：2017-06-29

申请号：US15457893

申请日：2017-03-13

Applicant: Janssen Biotech, Inc.

Inventor： Janet Davis ,  Jiajian Liu ,  Christine Parmenter ,  Pascal Ghislain Andre Bonnet

IPC: C12N5/0735

CPC classification number: C12N5/0606 ,  C12N5/0676 ,  C12N5/0678 ,  C12N2500/25 ,  C12N2501/11 ,  C12N2501/115 ,  C12N2501/119 ,  C12N2501/135 ,  C12N2501/15 ,  C12N2501/155 ,  C12N2501/16 ,  C12N2501/165 ,  C12N2501/19 ,  C12N2501/385 ,  C12N2501/41 ,  C12N2501/415 ,  C12N2501/42 ,  C12N2501/727 ,  C12N2501/845 ,  C12N2501/999 ,  C12N2506/02 ,  C12N2531/00 ,  C12N2533/50 ,  C12N2533/90

Abstract: The present invention is directed to methods to differentiate pluripotent stem cells. In particular, the present invention is directed to methods and compositions to differentiate pluripotent stem cells into cells expressing markers characteristic of the definitive endoderm lineage comprising culturing the pluripotent stem cells in medium comprising a sufficient amount of GDF-8 to cause the differentiation of the pluripotent stem cells into cells expressing markers characteristic of the definitive endoderm lineage.

公开(公告)号：US09845460B2

公开(公告)日：2017-12-19

申请号：US14085068

申请日：2013-11-20

Applicant: Janssen Biotech, Inc.

Inventor： Janet Davis ,  Jiajian Liu

IPC: A61K31/00 ,  C12N5/02 ,  C12N5/08 ,  C12N5/071 ,  C12N5/0735

CPC classification number: C12N5/0676 ,  A61K31/00 ,  C12N5/0606 ,  C12N2501/105 ,  C12N2501/115 ,  C12N2501/117 ,  C12N2501/119 ,  C12N2501/16 ,  C12N2501/415 ,  C12N2501/48 ,  C12N2501/70 ,  C12N2506/00 ,  C12N2506/02

Abstract: The present invention is provides a method for treating human pluripotent cells. In particular, the methods of the invention are directed to the treatment of human pluripotent cells, whereby the human pluripotent cells can be efficiently expanded in culture and differentiated by treating the pluripotent cells with an inhibitor of glycogen synthase kinase 3β (GSK-3B) enzyme activity.

公开(公告)号：US20140080210A1

公开(公告)日：2014-03-20

申请号：US14085068

申请日：2013-11-20

Applicant: Janssen Biotech, Inc.

Inventor： Janet Davis ,  Jiajian Liu

IPC: C12N5/071

CPC classification number: C12N5/0676 ,  A61K31/00 ,  C12N5/0606 ,  C12N2501/105 ,  C12N2501/115 ,  C12N2501/117 ,  C12N2501/119 ,  C12N2501/16 ,  C12N2501/415 ,  C12N2501/48 ,  C12N2501/70 ,  C12N2506/00 ,  C12N2506/02

Abstract: The present invention is directed to methods to treat pluripotent cells, whereby the pluripotent cells can be efficiently expanded in culture and differentiated by treating the pluripotent cells with an inhibitor of GSK-3B enzyme activity.

Abstract translation: 本发明涉及治疗多能细胞的方法，其中多能细胞可以通过用GSK-3B酶活性抑制剂处理多能细胞而在培养中有效扩增并分化。

公开(公告)号：US20180127723A1

公开(公告)日：2018-05-10

申请号：US15845393

申请日：2017-12-18

Applicant: Janssen Biotech, Inc.

Inventor： Janet Davis ,  Jiajian Liu

IPC: C12N5/071 ,  C12N5/0735 ,  A61K31/00

CPC classification number: C12N5/0676 ,  A61K31/00 ,  C12N5/0606 ,  C12N2501/105 ,  C12N2501/115 ,  C12N2501/117 ,  C12N2501/119 ,  C12N2501/16 ,  C12N2501/415 ,  C12N2501/48 ,  C12N2501/70 ,  C12N2506/00 ,  C12N2506/02

Abstract: The present invention provides a method for treating human pluripotent cells. In particular, the methods of the invention are directed to the treatment of human pluripotent cells, whereby the human pluripotent cells can be efficiently expanded in culture and differentiated by treating the pluripotent cells with an inhibitor of glycogen synthase kinase 3β (GSK-3B) enzyme activity.

公开(公告)号：US20170183624A1

公开(公告)日：2017-06-29

申请号：US15457864

申请日：2017-03-13

Applicant: Janssen Biotech, Inc.

Inventor： Janet Davis ,  Jiajian Liu ,  Christine Parmenter ,  Pascal Ghislain Andre Bonnet

IPC: C12N5/0735

CPC classification number: C12N5/0606 ,  C12N5/0676 ,  C12N5/0678 ,  C12N2500/25 ,  C12N2501/11 ,  C12N2501/115 ,  C12N2501/119 ,  C12N2501/135 ,  C12N2501/15 ,  C12N2501/155 ,  C12N2501/16 ,  C12N2501/165 ,  C12N2501/19 ,  C12N2501/385 ,  C12N2501/41 ,  C12N2501/415 ,  C12N2501/42 ,  C12N2501/727 ,  C12N2501/845 ,  C12N2501/999 ,  C12N2506/02 ,  C12N2531/00 ,  C12N2533/50 ,  C12N2533/90

Abstract: The present invention is directed to methods to differentiate pluripotent stem cells. In particular, the present invention is directed to methods and compositions to differentiate pluripotent stem cells into cells expressing markers characteristic of the definitive endoderm lineage comprising culturing the pluripotent stem cells in medium comprising a sufficient amount of GDF-8 to cause the differentiation of the pluripotent stem cells into cells expressing markers characteristic of the definitive endoderm lineage.